This viewpoint article critiques two recent articles examining ‘willingness to risk death’ to advance HIV cure-related research. The ‘willingness to risk death’ endpoint sends the wrong signal to the HIV cure-related research community about ongoing research in otherwise healthy volunteers living with HIV. Socio-behavioural scientists have examined the acceptability of a 99% risk of death scenario, which is unrealistic and would not be acceptable by current regulatory and ethical standards.
We believe that the field needs robust and relevant socio-behavioural research reflecting ongoing biomedical HIV cure-related trials. These studies will need to withstand regulatory and ethical scrutiny if cure or remission regimens are to proceed to the licensing stage.
The HIV cure-related research community must continue to protect the public trust in the HIV cure-related research field and sustain societal value generated by such research. We call for the utmost prudence in designing biomedical HIV cure trials as well as in setting up socio-behavioural research experiments related to these complex trials.
Left behind: persons with disabilities in HIV prevalence research and national strategic plans in east and Southern Africa.
Purpose: To assess recent estimates of HIV prevalence and the inclusion of persons with disabilities in the HIV response in sub-Saharan Africa.
Methods: A systematic literature search was conducted of recent HIV prevalence studies among persons with disabilities in sub-Saharan Africa and National Strategic Plans from 18 countries in east and southern Africa were reviewed. Results were compared to a 2014 literature search and a 2009 National Strategic Plans review that used similar methods.
Results: Between 2013 and 2018, four published studies were identified with estimates of HIV prevalence among persons with disabilities in sub-Saharan Africa. In each study, HIV prevalence was higher among persons with disabilities than national population estimates. Fourteen of the 18 National Strategic Plans reviewed identified persons with disabilities as a vulnerable or marginalized population and thirteen National Strategic Plans proposed targeted programs for persons with disabilities. Among seven assessed disability inclusion indicators of National Strategic Plans, four showed some improvement, two showed no change, and one regressed compared to the 2009 analysis.
RhoA Activation Assay |
|||
| STA-403-A | Cell Biolabs | 20 assays | 556 EUR |
RhoB Activation Assay |
|||
| STA-403-B | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Rho Activation Assays use visible agarose beads to selectively precipitate the active form of RhoA, RhoB or RhoC. The precipitated small GTPase is then detected by Western blot using a RhoA-, RhoB- or RhoC-specific antibody included in the kit. |
|||
RhoC Activation Assay |
|||
| STA-403-C | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Rho Activation Assays use visible agarose beads to selectively precipitate the active form of RhoA, RhoB or RhoC. The precipitated small GTPase is then detected by Western blot using a RhoA-, RhoB- or RhoC-specific antibody included in the kit. |
|||
Arf1 Activation Assay |
|||
| STA-407-1 | Cell Biolabs | 20 assays | 665 EUR |
Arf6 Activation Assay |
|||
| STA-407-6 | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Arf Activation Assays use visible agarose beads to selectively precipitate the active form of Arf1 or Arf 6. The precipitated small GTPase is then detected by Western blot using an Arf1- or Arf6-specific antibody included in the kit. |
|||
Cdc42 Activation Assay |
|||
| STA-402 | Cell Biolabs | 20 assays | 556 EUR |
H-Ras Activation Assay |
|||
| STA-400-H | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
K-Ras Activation Assay |
|||
| STA-400-K | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
N-Ras Activation Assay |
|||
| STA-400-N | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
Rap1 Activation Assay Kit |
|||
| STA-406-1 | Cell Biolabs | 20 assays | 556 EUR |
Rap2 Activation Assay Kit |
|||
| STA-406-2 | Cell Biolabs | 20 assays | 908.4 EUR |
|
Description: Our Rap Activation Assays use visible agarose beads to selectively precipitate the active form of Rap1 or Rap2. The precipitated small GTPase is then detected by Western blot using a Rap1- or Rap2-specific antibody included in the kit. |
|||
Pan-Ras Activation Assay |
|||
| STA-400 | Cell Biolabs | 20 assays | 556 EUR |
Ral Activation Assay Kit, Trial Size |
|||
| STA-408-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ral Activation Assay uses visible agarose beads to selectively precipitate the active form of Ral protein. The precipitated small GTPase is then detected by Western blot using a Ral-specific antibody included in the kit. |
|||
Ran Activation Assay Kit, Trial Size |
|||
| STA-409-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ran Activation Assay uses visible agarose beads to selectively precipitate the active form of Ran protein. The precipitated small GTPase is then detected by Western blot using a Ran-specific antibody included in the kit. |
|||
Rac1 Activation Assay Kit, Trial Size |
|||
| STA-401-1-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rac Activation Assays use visible agarose beads to selectively precipitate the active form of Rac1 or Rac2. The precipitated small GTPase is then detected by Western blot using a Rac1- or Rac2-specific antibody included in the kit. |
|||
Rac2 Activation Assay Kit, Trial Size |
|||
| STA-401-2-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rac Activation Assays use visible agarose beads to selectively precipitate the active form of Rac1 or Rac2. The precipitated small GTPase is then detected by Western blot using a Rac1- or Rac2-specific antibody included in the kit. |
|||
RhoA Activation Assay Kit, Trial Size |
|||
| STA-403-A-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rho Activation Assays use visible agarose beads to selectively precipitate the active form of RhoA, RhoB or RhoC. The precipitated small GTPase is then detected by Western blot using a RhoA-, RhoB- or RhoC-specific antibody included in the kit. |
|||
RhoB Activation Assay Kit, Trial Size |
|||
| STA-403-B-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rho Activation Assays use visible agarose beads to selectively precipitate the active form of RhoA, RhoB or RhoC. The precipitated small GTPase is then detected by Western blot using a RhoA-, RhoB- or RhoC-specific antibody included in the kit. |
|||
RhoC Activation Assay Kit, Trial Size |
|||
| STA-403-C-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rho Activation Assays use visible agarose beads to selectively precipitate the active form of RhoA, RhoB or RhoC. The precipitated small GTPase is then detected by Western blot using a RhoA-, RhoB- or RhoC-specific antibody included in the kit. |
|||
Rap1 Activation Assay Kit, Trial Size |
|||
| STA-406-1-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rap Activation Assays use visible agarose beads to selectively precipitate the active form of Rap1 or Rap2. The precipitated small GTPase is then detected by Western blot using a Rap1- or Rap2-specific antibody included in the kit. |
|||
Rap2 Activation Assay Kit, Trial Size |
|||
| STA-406-2-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Rap Activation Assays use visible agarose beads to selectively precipitate the active form of Rap1 or Rap2. The precipitated small GTPase is then detected by Western blot using a Rap1- or Rap2-specific antibody included in the kit. |
|||
Arf1 Activation Assay Kit, Trial Size |
|||
| STA-407-1-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Arf Activation Assays use visible agarose beads to selectively precipitate the active form of Arf1 or Arf 6. The precipitated small GTPase is then detected by Western blot using an Arf1- or Arf6-specific antibody included in the kit. |
|||
Arf6 Activation Assay Kit, Trial Size |
|||
| STA-407-6-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Arf Activation Assays use visible agarose beads to selectively precipitate the active form of Arf1 or Arf 6. The precipitated small GTPase is then detected by Western blot using an Arf1- or Arf6-specific antibody included in the kit. |
|||
Cdc42 Activation Assay Kit, Trial Size |
|||
| STA-402-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Cdc42 Activation Assays use visible agarose beads to selectively precipitate the active form of Cdc42 protein. The precipitated small GTPase is then detected by Western blot using a Cdc42-specific antibody included in the kit. |
|||
Rac1/Cdc42 Activation Assay Combo Kit |
|||
| STA-404 | Cell Biolabs | 2 x 20 assays | 796 EUR |
H-Ras Activation Assay Kit, Trial Size |
|||
| STA-400-H-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
K-Ras Activation Assay Kit, Trial Size |
|||
| STA-400-K-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
N-Ras Activation Assay Kit, Trial Size |
|||
| STA-400-N-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
Pan-Ras Activation Assay Kit, Trial Size |
|||
| STA-400-T | Cell Biolabs | 5 assays | 483.6 EUR |
|
Description: Our Ras Activation Assays use visible agarose beads to selectively precipitate the active form of specific Ras protein of interest. The precipitated small GTPase is then detected by Western blot using a target-specific antibody included in the kit. Assays are available to detect specific isoforms H-Ras, K-Ras, and N-Ras, as well as a Pan-Ras assay that detects all three isoforms. |
|||
RhoA/Rac1/Cdc42 Activation Assay Combo Kit |
|||
| STA-405 | Cell Biolabs | 3 x 10 assays | 796 EUR |
96-Well Ras Activation ELISA Kit (Colorimetric) |
|||
| STA-440 | Cell Biolabs | 96 assays | 672 EUR |
|
Description: Excepted Quantities |
|||
96-Well Ras Activation ELISA Kit (Chemiluminescent) |
|||
| STA-441 | Cell Biolabs | 96 assays | 810 EUR |
NK Cell Activation Structures (Natural Killer Cell Activation Structures) |
|||
| MBS609698-1mL | MyBiosource | 1mL | 975 EUR |
NK Cell Activation Structures (Natural Killer Cell Activation Structures) |
|||
| MBS609698-5x1mL | MyBiosource | 5x1mL | 4245 EUR |
Anti-Rat NK Cell activation structure antibody |
|||
| STJ16100720 | St John's Laboratory | 1 mL | 754.8 EUR |
Rat Monoclonal anti-Mouse/Human GL7 Antigen (T and B cell Activation Marker) Antibody |
|||
| xAP-0845 | Angio Proteomie | 100ug | 280 EUR |
Human B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| IHUBCM1KT | Innovative research | each | 890 EUR |
|
Description: Human B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
Mouse B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| IMSBCM1KT | Innovative research | each | 890 EUR |
|
Description: Mouse B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
Human B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| MBS137915-1Kit | MyBiosource | 1Kit | 755 EUR |
Human B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| MBS137915-5x1Kit | MyBiosource | 5x1Kit | 3455 EUR |
Mouse B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| MBS8420383-1Kit | MyBiosource | 1Kit | 755 EUR |
Mouse B-Lymphocyte Activation Marker (CD48) ELISA Kit |
|||
| MBS8420383-5x1Kit | MyBiosource | 5x1Kit | 3455 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381431-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381431-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381431-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381431-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381431-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381710-05mL | MyBiosource | 0.5mL | 405 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4381710-5x05mL | MyBiosource | 5x0.5mL | 1725 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4380744-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | 230 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4380744-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | 405 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4380744-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | 405 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4380744-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | 1725 EUR |
CD40 Ligand/CD154/TRAP1 (Activation Marker of T-Lymphocytes) |
|||
| MBS4380744-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | 1725 EUR |
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), 1mg/mL |
|||
| BNUM2761-50 | Biotium | 1uL | 396 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), 1mg/mL |
|||
| BNUM2763-50 | Biotium | 1uL | 396 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), 0.2mg/mL |
|||
| BNUB2761-100 | Biotium | 1uL | 225 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), 0.2mg/mL |
|||
| BNUB2761-500 | Biotium | 1uL | 485 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), 0.2mg/mL |
|||
| BNUB2763-100 | Biotium | 1uL | 225 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), 0.2mg/mL |
|||
| BNUB2763-500 | Biotium | 1uL | 485 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF568 conjugate, 0.1mg/mL |
|||
| BNC682761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF568 conjugate, 0.1mg/mL |
|||
| BNC682761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF568 conjugate, 0.1mg/mL |
|||
| BNC682763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF568 conjugate, 0.1mg/mL |
|||
| BNC682763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF594 conjugate, 0.1mg/mL |
|||
| BNC942761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF594 conjugate, 0.1mg/mL |
|||
| BNC942761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF594 conjugate, 0.1mg/mL |
|||
| BNC942763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF594 conjugate, 0.1mg/mL |
|||
| BNC942763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF647 conjugate, 0.1mg/mL |
|||
| BNC472761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF647 conjugate, 0.1mg/mL |
|||
| BNC472761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF647 conjugate, 0.1mg/mL |
|||
| BNC472763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF647 conjugate, 0.1mg/mL |
|||
| BNC472763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (AP) |
|||
| MBS6372960-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (AP) |
|||
| MBS6372960-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) APC |
|||
| MBS6372961-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) APC |
|||
| MBS6372961-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (Biotin) |
|||
| MBS6372962-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (Biotin) |
|||
| MBS6372962-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (FITC) |
|||
| MBS6372963-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (FITC) |
|||
| MBS6372963-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (HRP) |
|||
| MBS6372964-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (HRP) |
|||
| MBS6372964-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (PE) |
|||
| MBS6372970-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (PE) |
|||
| MBS6372970-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF488A conjugate, 0.1mg/mL |
|||
| BNC882761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF488A conjugate, 0.1mg/mL |
|||
| BNC882761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF488A conjugate, 0.1mg/mL |
|||
| BNC882763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF488A conjugate, 0.1mg/mL |
|||
| BNC882763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), Biotin conjugate, 0.1mg/mL |
|||
| BNCB2761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), Biotin conjugate, 0.1mg/mL |
|||
| BNCB2761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), Biotin conjugate, 0.1mg/mL |
|||
| BNCB2763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), Biotin conjugate, 0.1mg/mL |
|||
| BNCB2763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF640R conjugate, 0.1mg/mL |
|||
| BNC402761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF640R conjugate, 0.1mg/mL |
|||
| BNC402761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF640R conjugate, 0.1mg/mL |
|||
| BNC402763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF640R conjugate, 0.1mg/mL |
|||
| BNC402763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF405S conjugate, 0.1mg/mL |
|||
| BNC042761-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2761), CF405S conjugate, 0.1mg/mL |
|||
| BNC042761-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF405S conjugate, 0.1mg/mL |
|||
| BNC042763-100 | Biotium | 1uL | 192 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD40 Ligand / CD154 / TRAP1 (Activation Marker of T-Lymphocytes)(CD40LG/2763), CF405S conjugate, 0.1mg/mL |
|||
| BNC042763-500 | Biotium | 1uL | 532 EUR |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 405) |
|||
| MBS6372965-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 405) |
|||
| MBS6372965-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 490) |
|||
| MBS6372966-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 490) |
|||
| MBS6372966-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 550) |
|||
| MBS6372967-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 550) |
|||
| MBS6372967-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 650) |
|||
| MBS6372968-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 650) |
|||
| MBS6372968-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 750) |
|||
| MBS6372969-01mL | MyBiosource | 0.1mL | 920 EUR |
CD244 (Natural Killer Cell Receptor 2B4, NK Cell Activation-inducing Ligand, NAIL, NK Cell Type I Receptor Protein 2B4, NKR2B4, h2B4, SLAM Family Member 4, SLAMF4, Signaling Lymphocytic Activation Molecule 4, 2B4, h2B4) (MaxLight 750) |
|||
| MBS6372969-5x01mL | MyBiosource | 5x0.1mL | 3990 EUR |
Rat B Cell Activation Factor ELISA kit |
|||
| E01A10465 | BlueGene | 96T | 700 EUR |
|
Description: ELISA |
|||
Rat B Cell Activation Factor ELISA kit |
|||
| E02B0309-192T | BlueGene | 192 tests | 1524 EUR |
|
Description: A competitive ELISA for quantitative measurement of Rat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat B Cell Activation Factor ELISA kit |
|||
| E02B0309-48 | BlueGene | 1 plate of 48 wells | 624 EUR |
|
Description: A competitive ELISA for quantitative measurement of Rat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat B Cell Activation Factor ELISA kit |
|||
| E02B0309-48wellsplate | BlueGene | 48 wells plate | 280 EUR |
Rat B Cell Activation Factor ELISA kit |
|||
| E02B0309-96 | BlueGene | 1 plate of 96 wells | 822 EUR |
|
Description: A competitive ELISA for quantitative measurement of Rat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Rat B Cell Activation Factor ELISA kit |
|||
| E02B0309-96wellsplate | BlueGene | 96 wells plate | 405 EUR |
Pig B Cell Activation Factor ELISA kit |
|||
| E07B0309-192T | BlueGene | 192 tests | 1524 EUR |
|
Description: A competitive ELISA for quantitative measurement of Porcine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig B Cell Activation Factor ELISA kit |
|||
| E07B0309-48 | BlueGene | 1 plate of 48 wells | 624 EUR |
|
Description: A competitive ELISA for quantitative measurement of Porcine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Pig B Cell Activation Factor ELISA kit |
|||
| E07B0309-96 | BlueGene | 1 plate of 96 wells | 822 EUR |
|
Description: A competitive ELISA for quantitative measurement of Porcine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog B Cell Activation Factor ELISA kit |
|||
| E08B0309-192T | BlueGene | 192 tests | 1524 EUR |
|
Description: A competitive ELISA for quantitative measurement of Canine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog B Cell Activation Factor ELISA kit |
|||
| E08B0309-48 | BlueGene | 1 plate of 48 wells | 624 EUR |
|
Description: A competitive ELISA for quantitative measurement of Canine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Dog B Cell Activation Factor ELISA kit |
|||
| E08B0309-96 | BlueGene | 1 plate of 96 wells | 822 EUR |
|
Description: A competitive ELISA for quantitative measurement of Canine B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat B Cell Activation Factor ELISA kit |
|||
| E01A45377 | BlueGene | 96T | 700 EUR |
|
Description: ELISA |
|||
Goat B Cell Activation Factor ELISA kit |
|||
| E06B0309-192T | BlueGene | 192 tests | 1524 EUR |
|
Description: A competitive ELISA for quantitative measurement of Goat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat B Cell Activation Factor ELISA kit |
|||
| E06B0309-48 | BlueGene | 1 plate of 48 wells | 624 EUR |
|
Description: A competitive ELISA for quantitative measurement of Goat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat B Cell Activation Factor ELISA kit |
|||
| E06B0309-48wellsplate | BlueGene | 48 wells plate | 280 EUR |
Goat B Cell Activation Factor ELISA kit |
|||
| E06B0309-96 | BlueGene | 1 plate of 96 wells | 822 EUR |
|
Description: A competitive ELISA for quantitative measurement of Goat B Cell Activation Factor in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
|||
Goat B Cell Activation Factor ELISA kit |
|||
| E06B0309-96wellsplate | BlueGene | 96 wells plate | 405 EUR |
Mouse B Cell Activation Factor ELISA kit |
|||
| E01A19206 | BlueGene | 96T | 700 EUR |
|
Description: ELISA |
|||
Conclusions: Data on HIV prevalence among persons with disabilities is rare. In addition, inclusion of this population in National Strategic Plans in East and Southern African countries is often lacking specific detail.Implications for rehabilitationHIV prevalence studies in sub-Saharan Africa among persons with disabilities are rare and community studies do not disaggregate by type of disability.Estimates of HIV prevalence among persons with disabilities are greater than national averages.
Government National HIV Strategic Plans often mention persons with disabilities as a vulnerable population but less often identify specific interventions or inclusive strategies for prevention or care.
The integration of attention to disability in national HIV bio-behavioral surveys would allow increased understanding of HIV vulnerability and prevalence and could increase attention to persons with disabilities as a key population within National Strategic Plans.